Welcome to our dedicated page for INSPIRE VETERINARY PARTNER SEC filings (Ticker: IVP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Inspire Veterinary Partners, Inc. (NASDAQ: IVP) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including Forms 10-K, 10-Q, 8-K, proxy statements, and registration statements. These documents offer detailed insight into IVP’s veterinary hospital operations, financial condition, risk factors, and capital structure.
Through recent Form 8-K filings, Inspire has reported material events such as notices from the Nasdaq Stock Market regarding minimum bid price compliance, the scheduling of a Nasdaq hearings panel review, changes in its independent registered public accounting firm, the issuance of senior convertible promissory notes, and equity issuances related to consulting agreements and debt cancellation. These filings explain key terms of financing arrangements, conversion features, and potential dilution, and they describe events of default and use of proceeds.
The company’s S-1 registration statements describe its business model as an owner and operator of veterinary hospitals across the United States, outline services offered at its clinics, and provide extensive risk factor disclosures covering profitability, acquisition strategy, regulatory exposure, internal controls, and listing considerations. Proxy materials on Schedule 14A detail matters submitted to stockholders, such as director elections and auditor ratification, and explain voting rights associated with Class A and Class B common stock.
On Stock Titan, these filings are complemented by AI-powered summaries that highlight the most important points in lengthy documents, helping readers quickly understand issues such as new debt or equity financings, changes in auditors, Nasdaq listing status, and governance matters. Users can review annual reports on Form 10-K and quarterly reports on Form 10-Q for comprehensive financial statements and management discussion, and monitor 8-Ks for real-time updates on significant corporate events. Insider ownership and equity incentive information can be explored through proxy statements and related filings.
By using this page, investors and researchers can efficiently navigate Inspire Veterinary Partners’ SEC reporting history, compare successive filings, and see how the company’s financial and regulatory profile develops over time.
Laura Elizabeth Johnson, Vice President of Operations and a director-level reporting person for Inspire Veterinary Partners, Inc. (IVP), filed an initial Form 3 reporting the event dated 08/20/2025. The filing lists the reporting persons name and business address and explicitly states no securities are beneficially owned. The form is signed and dated 08/22/2025.
Armistice Capital, LLC and Steven Boyd report a 9.99% beneficial stake in Inspire Veterinary Partners, Inc. The Schedule 13G/A shows Armistice Capital (Delaware) and Steven Boyd (U.S.) collectively beneficially own 228,584 shares of Class A common stock (CUSIP G0360L134). The filing attributes shared voting and dispositive power over all 228,584 shares and reports no sole voting or dispositive power. The reporting parties say the shares are held in the ordinary course of business and not to influence control. The statement notes the Master Fund is the direct holder and Armistice Capital acts as investment manager.
Anne Murphy, identified as a director of Inspire Veterinary Partners, Inc. (ticker: IVP), reported a derivative security transaction on Form 4. The filing discloses an acquisition dated 09/26/2024 of a stock option (right to buy) covering 1,447 shares of Class A common stock with an exercise price of $17 per share. The options are shown as exercisable on 09/26/2024 and expiring on 09/26/2034, and the reported post-transaction beneficial ownership is 1,447 shares held directly.
The form notes that reported share counts have been adjusted for a 25-for-1 reverse stock split effected on 01/27/2025. The filing states it was submitted late due to an "inadvertent administrative error" and is signed by Anne Murphy with a signature date of 08/08/2025.
Inspire Veterinary Partners, Inc. disclosed that holders of a majority (78.4%) of its voting power approved, by written consent dated July 24, 2025, a Private Placement consisting of (i) a Securities Purchase Agreement (July 28, 2025) providing for up to $10.0 million of Series B convertible preferred stock and accompanying warrants and (ii) a Common Stock Purchase Agreement (ELOC Agreement, July 29, 2025) under which an accredited investor may purchase up to $50.0 million of Common Stock. The Company completed an initial closing on July 29, 2025, issuing 6,340 shares of Series B preferred stock and 6,340,000 warrants for approximately $6.0 million in proceeds.
The warrants have a five-year term and an initial $1.00 exercise price, with conversion and exercise prices subject to downward adjustment but floored near $0.1876–$0.1879. Series B conversions and ELOC purchases are subject to beneficial ownership limits (generally 4.99%) and Nasdaq listing rules; the Majority Stockholders’ approval was obtained to permit issuances that would otherwise exceed Nasdaq’s Exchange Cap. The Series B terms include covenants restricting dividends, repurchases and certain indebtedness and require the Company to reserve significant authorized shares to satisfy conversions, all of which may materially dilute existing holders and affect voting/economic interests.
Lawrence Alexander, a director of Inspire Veterinary Partners, reported acquiring stock options that give the right to purchase 1,447 shares of Class A Common Stock at an exercise price of $17. The options were recorded with a transaction date of 09/26/2024, are exercisable on 09/26/2024 and expire on 09/26/2034, and are held in a direct ownership form.
The filing notes a corporate action that adjusted reported share counts: the issuer effected a 25-to-1 reverse stock split on 01/27/2025, and the numbers on this Form 4 were updated to reflect that split. The report shows 1,447 options outstanding following the transaction, representing the right to buy 1,447 Class A shares at the stated price until 2034.
Charles Stith Keiser, a director of Inspire Veterinary Partners, Inc. (IVP), reported exercising stock options on 09/26/2024 to acquire 953 shares of Class A Common Stock at an exercise price of $17 per share. The transaction is reported as a direct acquisition and the Form 4 notes that the share amounts have been adjusted for a 25-for-1 reverse stock split effected by the issuer on January 27, 2025. The filing states it was submitted late due to an inadvertent administrative error and is signed by Mr. Keiser on 08/07/2025.
Frank Richard, Chief Financial Officer of Inspire Veterinary Partners, Inc. (IVP), acquired 58,480 stock options on 04/01/2025. The options carry a $1.71 exercise price, are exercisable on 04/01/2025 and expire 04/01/2035, each covering one Class A common share. The reported ownership is direct. The Form 4 notes the filing was late due to an inadvertent administrative error and is signed 08/06/2025.
Kimball Carr, Chief Executive Officer, President and Chair acquired 92,593 Class A common shares by exercising stock options with a $1.62 exercise (conversion) price on 05/16/2025. The options were exercisable on 05/16/2025 and expire 05/16/2035. Following the reported transaction, 92,593 shares are beneficially owned directly. Remarks state the Form 4 was filed late due to an inadvertent administrative error.
INSPIRE Veterinary Partners officer Kees Lynley acquired 34,247 stock options exercisable immediately on 05/28/2025 with an exercise price of $1.52. Each option converts into one share of Class A Common Stock and the options expire on 05/28/2035. Following the transaction, the reporting person directly beneficially owns 34,247 derivative securities.
FAQ
What is the current stock price of INSPIRE VETERINARY PARTNER (IVP)?
What is the market cap of INSPIRE VETERINARY PARTNER (IVP)?
